Race on Weight-Loss Track: Johnson’s Olebotide NDA Accepted, Will It Reshape the Market Landscape?
June 10, 2026Johnson Pharmaceuticals’ self-developed GLP-1/GIP dual receptor agonist Olebotide injection has officially obtained acceptance for marketing authorization application from the China National Medical Products Administration. The indication is for long-term weight management in obese or overweight adults.…
Original URL: Click here to visit original article